Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial)

Umberto Benedetto*, Douglas G. Altman, Stephen Gerry, Alastair Gray, Belinda Lees, Gianni D. Angelini, Marcus Flather, David P. Taggart, On behalf of the ART (Arterial Revascularization Trial) Investigators

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)

4 Citations (Scopus)
217 Downloads (Pure)

Abstract

Background

There is still uncertainty about the safety of aprotinin for coronary artery bypass graft surgery. The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral versus single internal thoracic artery grafting. Many of the ART patients (≈30%) received perioperative aprotinin. We investigated the association between perioperative aprotinin administration and short‐term (in‐hospital) and long‐term outcomes by performing a post hoc analysis of the ART.

Methods and Results

Among patients enrolled in the ART (n=3102) from 2004 to 2007, we excluded those who did not undergo surgery (n=18) and those with no information about use of perioperative aprotinin (n=9). Finally, 836 of 3076 patients (27%) received aprotinin. Propensity matching was used to select 536 pairs for final comparison. Aprotinin was also associated with an increased risk of hospital mortality (9 [1.7%] versus 1 [0.2%]; odds ratio, 9.12; 95% confidence interval [CI], 1.15–72.2; P=0.03), intra‐aortic balloon pump insertion (37 [6.9%] versus 17 [3.2%]; odds ratio, 2.26; 95% CI, 1.26–4.07; P=0.006), and acute kidney injury (102 [19.0%] versus 76 [14.2%]; odds ratio, 1.42; 95% CI, 1.03–1.97; P=0.03). Aprotinin was not associated with a lower incidence of transfusion (37 [6.9%] versus 28 [5.2%]; odds ratio, 1.34; 95% CI, 0.81–2.23; P=0.25) and reexploration (26 [4.9%] versus 19 [3.5%]; hazard ratio, 1.39; 95% CI, 0.76–2.53; P=0.28). At 5 years, all‐cause mortality was significantly increased in the aprotinin group (56 [10.6%] versus 38 [7.3%]; hazard ratio, 1.51; 95% CI, 1.0–2.28; P=0.045).

Conclusions

In the present post hoc ART analysis, aprotinin was associated with a significantly increased risk of early and late mortality.

Original languageEnglish
Article numbere007570
Number of pages15
JournalJournal of the American Heart Association
Volume7
Issue number5
Early online date3 Mar 2018
DOIs
Publication statusPublished - 6 Mar 2018

Structured keywords

  • Centre for Surgical Research

Keywords

  • Aprotinin
  • Coronary artery bypass graft surgery
  • Outcomes
  • Propensity score matching
  • Surgery

Fingerprint Dive into the research topics of 'Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial)'. Together they form a unique fingerprint.

  • Cite this